BCL11A and MDR1 expressions have prognostic impact in patients with acute myeloid leukemia treated with chemotherapy

Pharmacogenomics
Guo XutaoXu Bing

Abstract

Acute myeloid leukemia (AML) is a heterogeneous malignant disease. Many different genetic factors can affect a patient's clinical outcome. The aim of this study was to assess the expression of BCL11A and MDR1 in AML patients, and its relation to clinical outcome. We grouped the 142 patients by the levels of BCL11A and MDR1 and identified three different subgroups: high BCL11A and high MDR1 (n = 47), low BCL11A and low MDR1 (n = 47) and high BCL11A alone or high MDR1 alone (n = 48). The results showed that AML patients with high BCL11A and MDR1 expression had the lowest complete remission and highest relapse rate. The median overall survival of the high BCL11A and high MDR1 group was the shortest among the three groups. With regards to overall survival, there were also significant differences among the groups (p < 0.001). High BCL11A and MDR1 expression was associated with a poor response to chemotherapy, and identified a subset of AML patients with a very poor prognosis.

References

Apr 24, 1999·Leukemia·O LegrandJ P Marie
Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards
Jan 1, 2013·Biomedical Reports·Yangjun GaoYangqiu Li
Dec 18, 2014·Blood·Gert Ossenkoppele, Bob Löwenberg
Jan 28, 2015·Nature Reviews. Clinical Oncology·Alessia Errico
Oct 16, 2015·Hematology/oncology and Stem Cell Therapy·Edward A CopelanBelinda R Avalos
Dec 29, 2015·Leukemia Research·Huiquan TaoBin Yin
Jul 7, 2016·Pharmacogenomics·Juan Eduardo Megías-VericatSalvador F Aliño
Dec 14, 2016·The New England Journal of Medicine·Elihu Estey
Apr 20, 2017·Journal of Hematology & Oncology·Caner Saygin, Hetty E Carraway
May 10, 2017·Journal of Photochemistry and Photobiology. B, Biology·Jing-Jing ChenXiang Li
May 24, 2017·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Motonori MizutaniShingo Yano
Jun 1, 2017·American Society of Clinical Oncology Educational Book·Courtney D DiNardoBruno C Medeiros

❮ Previous
Next ❯

Citations

Oct 28, 2019·Bioscience Reports·Jiawei YinFengyuan Che
Jul 7, 2020·Frontiers in Pharmacology·Hongyun ShiHua Wang
Mar 30, 2021·Molecular Pharmaceutics·Pratheppa RajagopalUma Maheswari Krishnan
Dec 24, 2021·Frontiers in Oncology·Lu-Lu WangHuirong Mai

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR

Software Mentioned

SPSS

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.